Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 8Uveal Melanoma 3Multiple Myeloma 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Eye Neoplasms 1

Interventions

Cyclophosphamide 62Dexamethasone 60Melphalan 54Peripheral Blood Stem Cell Transplantation 49Bortezomib 40Busulfan 39fludarabine phosphate 34Filgrastim 32Lenalidomide 30Thalidomide 27Tacrolimus 25Antilymphocyte Serum 23Radiotherapy 22Mycophenolic Acid 17Methotrexate 17Prednisone 15Etoposide 15sargramostim 14Cyclosporine 14fludarabine 12Methylprednisolone 11Granulocyte Colony-Stimulating Factor 11Calcium Dobesilate 11Whole-Body Irradiation 10Doxorubicin 9Carmustine 9pomalidomide 8Vincristine 8Interferon-alpha 8Cord Blood Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Plasma Cell × MAGEA3 protein, human × Clear all
NCT00090493 2013-06-24

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

University of Arkansas

Phase 2/3 Completed
4 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡